UTime Limited signs $10 million agreement for smart health devices with Tumu Vertex, entering the North American medical wearable market.
Quiver AI Summary
UTime Limited, a global technology company based in Shenzhen, announced a significant milestone with its Hong Kong subsidiary signing a nearly $10 million procurement agreement with Tumu Vertex LLC, a Denver-based organization. This partnership marks UTime's entry into the North American market for medical-grade smart wearables, with Tumu Vertex placing an order for 50,000 smart health devices, including blood pressure watches and ECG smart rings. UTime's CEO highlighted the collaboration as a key strategic move, facilitating the integration of FDA-certified monitoring technology into everyday wearables. Both companies will adhere to quality assurance protocols, and the first product deliveries are scheduled for early 2026. Tumu Vertex's CEO expressed confidence in UTime’s innovative technology, which will enhance their health service platform in the U.S. The agreement positions UTime to capitalize on the growing demand for health monitoring technologies.
Potential Positives
- UTime Limited has secured a significant procurement agreement worth nearly $10 million USD, enhancing its revenue stream and market presence.
- The company is making a crucial entry into the North American medical-grade smart wearable market by partnering with Tumu Vertex LLC, positioning itself strategically for future growth.
- The sale of 50,000 smart health devices highlights market recognition of UTime's technological capabilities and could lead to increased brand credibility and customer trust.
- This collaboration is expected to accelerate the development and implementation of next-generation health monitoring technologies within UTime’s product portfolio, aligning with the growing demand for health-conscious solutions.
Potential Negatives
- The company's reliance on a single substantial agreement with Tumu Vertex LLC may raise concerns about revenue concentration and dependency on the success of this partnership.
- The press release includes a significant disclaimer regarding forward-looking statements, highlighting potential risks and uncertainties that could impact future performance.
- The need for rigorous joint quality control procedures suggests concerns over product reliability and quality assurance, which could affect the company's reputation in a competitive market.
FAQ
What is UTime Limited's recent commercial breakthrough?
UTime Limited announced a $10 million procurement agreement with Tumu Vertex LLC for smart health devices.
How many smart health devices has Tumu Vertex ordered?
Tumu Vertex has ordered an initial 50,000 smart health devices from UTime, including blood pressure watches and ECG smart rings.
What products are included in UTime's agreement with Tumu Vertex?
The agreement includes the UT-168 BT Blood Pressure Watch, UT-368 4G Blood Pressure Watch, UR08 ECG Smart Ring, and UR01 Smart Ring.
When will the first batch of products be delivered?
The first batch of products is scheduled for delivery in the first quarter of 2026.
How does UTime plan to leverage this partnership?
UTime aims to consolidate its position in consumer electronics and accelerate development in the medical technology sector.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$WTO Hedge Fund Activity
We have seen 4 institutional investors add shares of $WTO stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GROUND SWELL CAPITAL, LLC removed 17,801 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $19,937
- CITADEL ADVISORS LLC added 16,791 shares (+inf%) to their portfolio in Q3 2025, for an estimated $18,805
- VIRTU FINANCIAL LLC removed 15,048 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $16,853
- UBS GROUP AG removed 10,743 shares (-99.3%) from their portfolio in Q3 2025, for an estimated $12,032
- XTX TOPCO LTD added 10,669 shares (+inf%) to their portfolio in Q3 2025, for an estimated $11,949
- BANK OF AMERICA CORP /DE/ added 7,153 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,011
- FEDERATION DES CAISSES DESJARDINS DU QUEBEC added 1 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SHENZHEN, China, Dec. 31, 2025 (GLOBE NEWSWIRE) -- UTime Limited (Nasdaq: WTO), a global technology company engaged in the design and development of mobile devices today announced a major commercial breakthrough. UTime’s Hong Kong subsidiary, UTime Technology (HK) Company Limited, has officially signed a smart health device procurement agreement worth nearly $10 million USD with Tumu Vertex LLC, a Denver-based entity, marking a crucial step in UTime's strategic deployment in the North American medical-grade smart wearable market.
Under the signed Sales Agreement, Tumu Vertex LLC has placed an initial purchase order for 50,000 premium smart health devices from UTime, comprising:
-
25,000 units of the UT-168 BT Blood Pressure Watch and 25,000 units of the UR08 ECG Smart Ring.
-
25,000 units of the UT-368 4G Blood Pressure Watch and 25,000 units of the UR01 Smart Ring
We believe this collaboration represents not only a breakthrough in volume but also brings us to a new level in technological integration. UTime's solution perfectly combines FDA-certified medical-grade monitoring technology with everyday wearable scenarios, representing the latest development trend in the smart health industry. The agreement follows internationally recognized trade frameworks, covering FOB Hong Kong delivery, phased payments, and standardized quality assurance systems.
"This cooperation represents a significant strategic breakthrough for us in the North American market," stated UTime's CEO during the signing ceremony. "As our important partner in Colorado, Tumu Vertex's order for 50,000 units demonstrates not only market recognition of our technological capabilities but also opens the door to the North American medical-grade wearable market. We aim to use this opportunity to accelerate the development and implementation of next-generation health monitoring technologies as part of our product portfolio."
The founder and Chief Executive Officer of Tumu Vertex LLC, Monil Hossain, commented: "UTime's technological innovation and product quality have deeply impressed us. These devices will be used for our smart health service platform in the United States, providing users with 24/7 health monitoring solutions. We look forward to establishing long-term strategic cooperation with UTime."
According to the agreement, the first batch of products will begin delivery in the first quarter of 2026, with all products undergoing joint quality control procedures established by both parties.
As populations worldwide are living longer and obtaining greater health awareness, UTime believes the smart health device market is primed for explosive growth. We believe this major purchase order will help consolidate UTime’s position in the consumer electronics field while laying a solid foundation for the company's strategic growth in the medical technology sector.
About UTime Limited
Trading under the NASDAQ ticker WTO, UTime Limited is engaged in the design, development, production, sales and brand operation of mobile devices and smart wearable devices and other technology in China and globally. The company aims to provide cost-effective products while serving a broad customer base.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. For additional risk factors, please review UTime Limited’s Annual Report on Form 20-F and other SEC filings. Forward-looking statements are made only as of the date of this release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required under applicable law.
Contact:
[email protected]
UTime Limited
7th Floor, Building 5A
Shenzhen Software Industry Base, Nanshan District
Shenzhen, People’s Republic of China 518061
Tel: (86) 755 865122